MedTrace Logo

Apixaban for Treatment of Embolic Stroke of Undetermined Source

NCT02427126 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 352

Last updated 2021-10-13

No results posted yet for this study

Summary

Multicentre (national, Germany), randomized (2x2 factorial), open, parallel group, active controlled, efficacy study (phase III)

Conditions

  • Embolic Stroke of Undetermined Source

Interventions

DRUG

Apixaban

Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery

DRUG

Aspirin

Acetylic Salicylic Acid 100mg o.d.; 12 Months

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Medtronic

    collaborator INDUSTRY

  • ZKS and IKEaB Tübingen

    collaborator UNKNOWN

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Tobias Geisler, Prof · Tübingen University Hospital

  • Sven Poli, Prof · Tübingen University Hospital

  • Schreieck Jürgen, Prof · Tübingen University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2020-08-31
Completion
2021-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02427126 on ClinicalTrials.gov